DK1471871T3 - Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin - Google Patents

Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin

Info

Publication number: DK1471871T3
Authority: DK; Denmark
Prior art keywords: erythropoietin; treatment; neurological dysfunction; dysfunction including; fructopyranose sulfamates
Prior art date: 2001-02-02

Application number

DK02724904T

Other languages

English (en)

Inventor

Salaman Carlos Plata

Virginia Smith-Swintosky

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-02

Filing date

2002-01-24

Publication date

2007-09-17

2002-01-24 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

2007-09-17 Application granted granted Critical

2007-09-17 Publication of DK1471871T3 publication Critical patent/DK1471871T3/da

Links

102000003951 Erythropoietin Human genes 0.000 title abstract 2
108090000394 Erythropoietin Proteins 0.000 title abstract 2
229940105423 erythropoietin Drugs 0.000 title abstract 2
-1 fructopyranose sulfamates Chemical class 0.000 title abstract 2
230000009251 neurologic dysfunction Effects 0.000 title abstract 2
208000015015 neurological dysfunction Diseases 0.000 title abstract 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 2
238000011262 co‐therapy Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

DK02724904T 2001-02-02 2002-01-24 Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin DK1471871T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26619401P	2001-02-02	2001-02-02
PCT/US2002/003096 WO2002064085A2 (en)	2001-02-02	2002-01-24	Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin

Publications (1)

Publication Number	Publication Date
DK1471871T3 true DK1471871T3 (da)	2007-09-17

Family

ID=23013568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02724904T DK1471871T3 (da)	2001-02-02	2002-01-24	Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin

Country Status (17)

Country	Link
US (2)	US6908902B2 (da)
EP (1)	EP1471871B1 (da)
JP (1)	JP2005501801A (da)
KR (1)	KR100896971B1 (da)
AT (1)	ATE361089T1 (da)
CA (1)	CA2437333A1 (da)
CY (1)	CY1106733T1 (da)
DE (1)	DE60219961T8 (da)
DK (1)	DK1471871T3 (da)
ES (1)	ES2284858T3 (da)
MX (1)	MXPA03006952A (da)
NO (1)	NO20033440L (da)
NZ (1)	NZ548578A (da)
PT (1)	PT1471871E (da)
RU (1)	RU2317086C2 (da)
WO (1)	WO2002064085A2 (da)
ZA (1)	ZA200306818B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080255093A1 (en) *	1999-06-14	2008-10-16	Tam Peter Y	Compositions and methods for treating obesity and related disorders
US7674776B2 (en)	1999-06-14	2010-03-09	Vivus, Inc.	Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) *	2006-10-27	2008-05-01	Tam Peter Y	Combination Therapy
DE60219961T8 (de) *	2001-02-02	2008-04-17	Ortho-Mcneil Pharmaceutical, Inc.	Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
CA2459146A1 (en) *	2001-08-30	2003-03-13	Ortho-Mcneil Pharmaceutical, Inc.	Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
US7439063B2 (en) *	2002-06-11	2008-10-21	Burnham Institute For Medical Research	Neuroprotective synergy of erythropoietin and insulin-like growth factors
US20030235576A1 (en) *	2002-06-15	2003-12-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	New drug combinations for the treatment of ischaemic conditions
DE10226814A1 (de) *	2002-06-15	2004-01-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände
ES2286453T3 (es) *	2002-09-17	2007-12-01	Motac Neuroscience Limited	Tratamiento de la discinesia.
EP1815854A1 (en) *	2002-09-17	2007-08-08	Motac Neuroscience Limited	Treatment of dyskenesia
US7388079B2 (en) *	2002-11-27	2008-06-17	The Regents Of The University Of California	Delivery of pharmaceutical agents via the human insulin receptor
AT500929B1 (de)	2004-11-09	2007-03-15	Medizinische Uni Wien Muw	Pharmazeutische zubereitung die erythropoietin enthält
JPWO2007020922A1 (ja) *	2005-08-17	2009-02-26	創戸苅	脳疾患の治療剤および予防剤
US8741260B2 (en) *	2005-10-07	2014-06-03	Armagen Technologies, Inc.	Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) *	2005-10-07	2012-02-28	Armagen Technologies, Inc.	Fusion proteins for delivery of erythropoietin to the CNS
US8759297B2 (en) *	2006-08-18	2014-06-24	Armagen Technologies, Inc.	Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
EP2150248A4 (en) *	2007-01-16	2011-06-29	Univ Johns Hopkins	GLUTAMATE RECEPTOR ANTAGONISTS AND METHOD OF USE
WO2008137066A1 (en) *	2007-05-02	2008-11-13	The Board Of Regents Of The University Of Oklahoma	Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
RU2335296C1 (ru) *	2007-06-26	2008-10-10	Сергей Марович Дудкин	Фармацевтическая композиция для профилактики и лечения неврологических заболеваний
AU2008282496B2 (en)	2007-07-27	2013-04-04	Armagen Technologies, Inc.	Methods and compositions for increasing alpha-iduronidase activity in the CNS
US20090291092A1 (en) *	2008-05-22	2009-11-26	Miller Guy M	Treatment of mitochondrial diseases with an erythropoietin mimetic
US8580298B2 (en)	2008-06-09	2013-11-12	Vivus, Inc.	Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) *	2008-06-09	2009-12-10	Thomas Najarian	Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
CA2748889A1 (en)	2009-03-18	2010-09-23	Armagen Technologies, Inc.	Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP2485761B1 (en)	2009-10-09	2019-02-27	Armagen, Inc.	Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
AU2012346448B2 (en)	2011-12-02	2017-09-14	Armagen, Inc.	Methods and compositions for increasing arylsulfatase A activity in the CNS
CN103316026B (zh)	2012-03-23	2016-05-11	中国人民解放军军事医学科学院毒物药物研究所	含芬特明和托吡酯的联合产品及其制备方法
EP2829270B1 (en)	2012-03-23	2020-11-11	Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China	Joint product containing synephrine and topiramate
CN102579367B (zh)	2012-03-23	2014-03-12	中国人民解放军军事医学科学院毒物药物研究所	托吡酯缓释药物组合物、其制备方法及用途
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
US10538589B2 (en)	2015-01-14	2020-01-21	Armagen Inc.	Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4513006A (en)	1983-09-26	1985-04-23	Mcneil Lab., Inc.	Anticonvulsant sulfamate derivatives
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
DK173067B1 (da)	1986-06-27	1999-12-13	Univ Washington	Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5242942A (en)	1992-04-28	1993-09-07	Mcneilab, Inc.	Anticonvulsant fructopyranose cyclic sulfites and sulfates
US6153407A (en)	1992-07-28	2000-11-28	Beth Israel Deaconess Medical Center	Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en)	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery
US5384327A (en)	1992-12-22	1995-01-24	Mcneilab, Inc.	Anticonvulsant sorbopyranose sulfamates
US5354934A (en)	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
NZ271181A (en)	1993-07-19	1998-06-26	Amgen Inc	Protein protection; method for stabilising aerosolised proteins by adding a water-soluble polar organic compound to the aqueous solution prior to aerosolisation
US5571787A (en)	1993-07-30	1996-11-05	Myelos Corporation	Prosaposin as a neurotrophic factor
US5700909A (en)	1993-07-30	1997-12-23	The Regents Of The University Of California	Prosaposin and cytokine-derived peptides
CN1057534C (zh)	1993-08-17	2000-10-18	柯瑞英-艾格公司	促红细胞生成素类似物
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5773569A (en)	1993-11-19	1998-06-30	Affymax Technologies N.V.	Compounds and peptides that bind to the erythropoietin receptor
CA2179733C (en) *	1993-12-23	2007-03-27	Michael J. Costanzo	Anticonvulsant pseudofructopyranose sulfamates
IL116085A (en)	1994-12-16	1999-12-31	Ortho Pharma Corp	Spray dried erythropoietin
US5767078A (en)	1995-06-07	1998-06-16	Johnson; Dana L.	Agonist peptide dimers
US5753694A (en)	1996-06-28	1998-05-19	Ortho Pharmaceutical Corporation	Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
WO1998000124A1 (en)	1996-06-28	1998-01-08	Ortho Pharmaceutical Corporation	Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
EP0964702B1 (en)	1996-08-02	2006-10-04	Ortho-McNeil Pharmaceutical, Inc.	Polypeptides having a single covalently bound n-terminal water-soluble polymer
JP4541539B2 (ja)	1997-07-23	2010-09-08	ロシュダイアグノスティックスゲーエムベーハー	内因性遺伝子活性化によるエリスロポエチンの製造
ES2208798T3 (es)	1997-09-01	2004-06-16	Aventis Pharma Deutschland Gmbh	Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
US6165783A (en)	1997-10-24	2000-12-26	Neuro Spheres Holdings Ltd.	Erythropoietin-mediated neurogenesis
WO1999051097A1 (en) *	1998-04-02	1999-10-14	Avicena Group, Inc.	Compositions containing a combination of a creatine compound and a second agent
DE69933216T2 (de)	1998-06-15	2007-09-20	GTC Biotherapeutics, Inc., Framingham	Erythropoietin-analog-menschliches serum-albumin fusionsprotein
WO2000061138A1 (en) *	1999-04-08	2000-10-19	Ortho-Mcneil Pharmaceutical, Inc.	Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
KR101012932B1 (ko) *	1999-04-13	2011-02-08	더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드	말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
CA2270795A1 (en) *	1999-05-05	2000-11-05	Gestilab Inc.	Neuroprotective compositions and uses thereof
DE60219961T8 (de) *	2001-02-02	2008-04-17	Ortho-Mcneil Pharmaceutical, Inc.	Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin

2002
- 2002-01-24 DE DE60219961T patent/DE60219961T8/de active Active
- 2002-01-24 WO PCT/US2002/003096 patent/WO2002064085A2/en not_active Ceased
- 2002-01-24 CA CA002437333A patent/CA2437333A1/en not_active Abandoned
- 2002-01-24 KR KR1020037010232A patent/KR100896971B1/ko not_active Expired - Fee Related
- 2002-01-24 DK DK02724904T patent/DK1471871T3/da active
- 2002-01-24 MX MXPA03006952A patent/MXPA03006952A/es active IP Right Grant
- 2002-01-24 ES ES02724904T patent/ES2284858T3/es not_active Expired - Lifetime
- 2002-01-24 RU RU2003124059/14A patent/RU2317086C2/ru not_active IP Right Cessation
- 2002-01-24 JP JP2002563882A patent/JP2005501801A/ja not_active Ceased
- 2002-01-24 US US10/056,828 patent/US6908902B2/en not_active Expired - Lifetime
- 2002-01-24 AT AT02724904T patent/ATE361089T1/de active
- 2002-01-24 NZ NZ548578A patent/NZ548578A/en not_active IP Right Cessation
- 2002-01-24 EP EP02724904A patent/EP1471871B1/en not_active Expired - Lifetime
- 2002-01-24 PT PT02724904T patent/PT1471871E/pt unknown
2003
- 2003-08-01 NO NO20033440A patent/NO20033440L/no not_active Application Discontinuation
- 2003-09-01 ZA ZA2003/06818A patent/ZA200306818B/en unknown
2005
- 2005-01-31 US US11/047,420 patent/US20050261182A1/en not_active Abandoned
2007
- 2007-07-13 CY CY20071100943T patent/CY1106733T1/el unknown

Also Published As

Publication number	Publication date
DE60219961D1 (de)	2007-06-14
RU2003124059A (ru)	2005-01-27
WO2002064085A3 (en)	2004-09-10
US20050261182A1 (en)	2005-11-24
DE60219961T8 (de)	2008-04-17
KR100896971B1 (ko)	2009-05-14
MXPA03006952A (es)	2004-10-15
RU2317086C2 (ru)	2008-02-20
EP1471871B1 (en)	2007-05-02
EP1471871A4 (en)	2005-11-09
ATE361089T1 (de)	2007-05-15
NO20033440L (no)	2003-09-29
ES2284858T3 (es)	2007-11-16
US6908902B2 (en)	2005-06-21
JP2005501801A (ja)	2005-01-20
ZA200306818B (en)	2005-02-23
NZ548578A (en)	2008-03-28
EP1471871A2 (en)	2004-11-03
PT1471871E (pt)	2007-06-05
US20020169109A1 (en)	2002-11-14
CA2437333A1 (en)	2002-08-22
DE60219961T2 (de)	2008-01-17
WO2002064085A2 (en)	2002-08-22
NO20033440D0 (no)	2003-08-01
KR20040011458A (ko)	2004-02-05
CY1106733T1 (el)	2012-05-23

Publication	Publication Date	Title
DK1471871T3 (da)	2007-09-17	Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin
MX237325B (es)	2006-05-30	Tratamiento para semilla con combinaciones de insecticidas
DK1660458T3 (da)	2012-05-07	2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet.
DK1539166T3 (da)	2008-10-20	Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
PT1322163E (pt)	2005-08-31	Tratamento de sementes com combinacoes de piretrinas/piretroides e clotianidina
DK1047428T3 (da)	2007-10-08	Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
MX238203B (es)	2006-06-28	Tratamiento de semillas con combinaciones de piretrinas, piretroides y tlametoxam.
DK1392292T3 (da)	2006-05-29	Pyranoindazoler og deres anvendelse til behandling af glaukom
ITBO20000453A0 (it)	2000-07-26	Apparecchiatura e procedimento per la sterilizzazione del terreno .
DE60200302D1 (de)	2004-05-06	Laseraugenbehandlungseinrichtung
DK1143917T3 (da)	2004-06-01	Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
NO20023944D0 (no)	2002-08-20	Blanding og metoder for behandling av epilepsi
IS6619A (is)	2002-11-14	S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum
DK1500395T3 (da)	2006-06-19	Reboxetin til behandling af fibromyalgi og andre somatoforme lidelser
ATE333439T1 (de)	2006-08-15	Pflanzenkläranlage
BR0103928B1 (pt)	2010-11-16	equipamento para tratamento de efluentes e estação para tratamento de efluentes.
ITRM20020308A1 (it)	2003-12-03	Apparecchiatura per trattamenti terapeutici, e relativo metodo.
FIU20010133U0 (fi)	2001-03-27	Jäteveden käsittelylaitteisto
DK1453783T3 (da)	2007-01-29	Substituerede arylcycloalkaner og deres anvendelse som anticancermidler
ATE374611T1 (de)	2007-10-15	Antitumor wirksame 2-alkoxyestradiolsulfamate
DE10157913B4 (de)	2005-03-10	Therapietisch
FI5249U1 (fi)	2002-02-19	Kantojenkäsittelylaitteisto
DK1274700T3 (da)	2005-02-21	Dihydrobenzopyraner, dihydrobenzothiopyraner og tetrahydroquinoliner til behandling af COX-2-medierede lidelser
FI5282U1 (fi)	2002-03-15	Jäteveden puhdistamo
ES1050173Y (es)	2002-06-16	Medalla con calendario perfeccionada.